MTVAMetaVia Inc.

Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare names now have potentially market-moving events scheduled throughout the remainder of 2026, positioning them among closely watched stocks in the biotech and healthcare sectors. $BCDA, $NTHI, $MTVA, $BGMS, $CMND

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR Newswire CAMBRIDGE, Mass., June 4, 2026 CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ --MetaVia Inc...

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH PR Newswire CAMBRIDGE, Mass., May 27, 2026 48 mg Cohort...

Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data on its MASH treatment, reversing Thursday's dip.read more...

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing peer-reviewed data supporting its anti-fibrotic MASH drug candidate.read more...

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH PR Newswire CAMBRIDGE, Mass., May 20, 2026 CAMBRIDGE, Mass., May 20, 2026 /PRNewswire...

Here are today’s most compelling market narratives. $NTHI, $AMST, $MTVA, $AGYS, $INM, $CODX

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific...